PMID- 29343473 OWN - NLM STAT- MEDLINE DCOM- 20190729 LR - 20190729 IS - 1526-632X (Electronic) IS - 0028-3878 (Linking) VI - 90 IP - 7 DP - 2018 Feb 13 TI - Smoking affects the interferon beta treatment response in multiple sclerosis. PG - e593-e600 LID - 10.1212/WNL.0000000000004949 [doi] AB - OBJECTIVE: To investigate whether smoking in patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon beta (IFN-beta) is associated with the relapse rate and whether there is an interaction between smoking and human leukocyte antigen (HLA)-DRB1*15:01, HLA-A*02:01, and the N-acetyltransferase-1 (NAT1) variant rs7388368A. METHODS: DNA from 834 IFN-beta-treated patients with RRMS from the Danish Multiple Sclerosis Biobank was extracted for genotyping. Information about relapses from 2 years before the start of treatment to either the end of treatment or the last follow-up visit was obtained from the Danish Multiple Sclerosis Treatment Register. Smoking information came from a comprehensive questionnaire. RESULTS: We found that the relapse rate in patients with RRMS during IFN-beta treatment was higher in smokers compared to nonsmokers, with an incidence rate ratio (IRR) of 1.20 (95% confidence interval [CI] 1.021-1.416, p = 0.027) and with an IRR increase of 27% per pack of cigarettes per day (IRR 1.27, 95% CI 1.056-1.537, p = 0.012). We found no association or interaction with HLA and the NAT1 variant. CONCLUSION: In this observational cohort study, we found that smoking is associated with increased relapse activity in patients with RRMS treated with IFN-beta, but we found no association or interaction with HLA or the NAT1 variant. CI - (c) 2018 American Academy of Neurology. FAU - Petersen, Eva R AU - Petersen ER AD - From the Danish Multiple Sclerosis Center (E.R.P., A.B.O., M.M., P.S.S., F.S., H.B.S.), Department of Neurology, and Danish Multiple Sclerosis Treatment Register (N.K.-H., M.M.), Rigshospitalet, University of Copenhagen; and Department of Clinical Epidemiology (N.K.-H), Clinical Institute, University of Aarhus, Denmark. Evarosapetersen@gmail.com. FAU - Oturai, Annette B AU - Oturai AB AD - From the Danish Multiple Sclerosis Center (E.R.P., A.B.O., M.M., P.S.S., F.S., H.B.S.), Department of Neurology, and Danish Multiple Sclerosis Treatment Register (N.K.-H., M.M.), Rigshospitalet, University of Copenhagen; and Department of Clinical Epidemiology (N.K.-H), Clinical Institute, University of Aarhus, Denmark. FAU - Koch-Henriksen, Nils AU - Koch-Henriksen N AD - From the Danish Multiple Sclerosis Center (E.R.P., A.B.O., M.M., P.S.S., F.S., H.B.S.), Department of Neurology, and Danish Multiple Sclerosis Treatment Register (N.K.-H., M.M.), Rigshospitalet, University of Copenhagen; and Department of Clinical Epidemiology (N.K.-H), Clinical Institute, University of Aarhus, Denmark. FAU - Magyari, Melinda AU - Magyari M AD - From the Danish Multiple Sclerosis Center (E.R.P., A.B.O., M.M., P.S.S., F.S., H.B.S.), Department of Neurology, and Danish Multiple Sclerosis Treatment Register (N.K.-H., M.M.), Rigshospitalet, University of Copenhagen; and Department of Clinical Epidemiology (N.K.-H), Clinical Institute, University of Aarhus, Denmark. FAU - Sorensen, Per S AU - Sorensen PS AD - From the Danish Multiple Sclerosis Center (E.R.P., A.B.O., M.M., P.S.S., F.S., H.B.S.), Department of Neurology, and Danish Multiple Sclerosis Treatment Register (N.K.-H., M.M.), Rigshospitalet, University of Copenhagen; and Department of Clinical Epidemiology (N.K.-H), Clinical Institute, University of Aarhus, Denmark. FAU - Sellebjerg, Finn AU - Sellebjerg F AD - From the Danish Multiple Sclerosis Center (E.R.P., A.B.O., M.M., P.S.S., F.S., H.B.S.), Department of Neurology, and Danish Multiple Sclerosis Treatment Register (N.K.-H., M.M.), Rigshospitalet, University of Copenhagen; and Department of Clinical Epidemiology (N.K.-H), Clinical Institute, University of Aarhus, Denmark. FAU - Sondergaard, Helle B AU - Sondergaard HB AD - From the Danish Multiple Sclerosis Center (E.R.P., A.B.O., M.M., P.S.S., F.S., H.B.S.), Department of Neurology, and Danish Multiple Sclerosis Treatment Register (N.K.-H., M.M.), Rigshospitalet, University of Copenhagen; and Department of Clinical Epidemiology (N.K.-H), Clinical Institute, University of Aarhus, Denmark. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20180117 PL - United States TA - Neurology JT - Neurology JID - 0401060 RN - 0 (HLA-A*02:01 antigen) RN - 0 (HLA-A2 Antigen) RN - 0 (HLA-DRB1 Chains) RN - 0 (HLA-DRB1*15:01 antigen) RN - 0 (Immunologic Factors) RN - 0 (Isoenzymes) RN - 77238-31-4 (Interferon-beta) RN - EC 2.3.1.5 (Arylamine N-Acetyltransferase) RN - EC 2.3.1.5 (N-acetyltransferase 1) MH - Adolescent MH - Adult MH - Aged MH - Arylamine N-Acetyltransferase/genetics MH - Cohort Studies MH - Female MH - Genetic Association Studies MH - HLA-A2 Antigen/genetics MH - HLA-DRB1 Chains/genetics MH - Humans MH - Immunologic Factors/*therapeutic use MH - Incidence MH - Interferon-beta/*therapeutic use MH - Isoenzymes/genetics MH - Male MH - Middle Aged MH - Multiple Sclerosis, Relapsing-Remitting/*complications/*drug therapy/epidemiology/genetics MH - Polymorphism, Single Nucleotide MH - Recurrence MH - *Smoking/epidemiology/genetics/immunology MH - Treatment Outcome MH - Young Adult EDAT- 2018/01/19 06:00 MHDA- 2019/07/30 06:00 CRDT- 2018/01/19 06:00 PHST- 2017/02/03 00:00 [received] PHST- 2017/11/02 00:00 [accepted] PHST- 2018/01/19 06:00 [pubmed] PHST- 2019/07/30 06:00 [medline] PHST- 2018/01/19 06:00 [entrez] AID - WNL.0000000000004949 [pii] AID - 10.1212/WNL.0000000000004949 [doi] PST - ppublish SO - Neurology. 2018 Feb 13;90(7):e593-e600. doi: 10.1212/WNL.0000000000004949. Epub 2018 Jan 17.